Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Capital Expenditures (2017 - 2025)

Historic Capital Expenditures for Puma Biotechnology (PBYI) over the last 7 years, with Q3 2025 value amounting to $26000.0.

  • Puma Biotechnology's Capital Expenditures rose 3000.0% to $26000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $123000.0, marking a year-over-year increase of 4470.59%. This contributed to the annual value of $56000.0 for FY2024, which is 6000.0% down from last year.
  • Per Puma Biotechnology's latest filing, its Capital Expenditures stood at $26000.0 for Q3 2025, which was up 3000.0% from $20000.0 recorded in Q2 2025.
  • Puma Biotechnology's 5-year Capital Expenditures high stood at $7.0 million for Q3 2022, and its period low was -$7.0 million during Q4 2022.
  • Over the past 4 years, Puma Biotechnology's median Capital Expenditures value was $23000.0 (recorded in 2024), while the average stood at $23500.0.
  • Over the last 5 years, Puma Biotechnology's Capital Expenditures had its largest YoY gain of 10064.29% in 2023, and its largest YoY loss of 9961.43% in 2023.
  • Puma Biotechnology's Capital Expenditures (Quarter) stood at -$7.0 million in 2022, then surged by 100.64% to $45000.0 in 2023, then crashed by 64.44% to $16000.0 in 2024, then surged by 62.5% to $26000.0 in 2025.
  • Its Capital Expenditures was $26000.0 in Q3 2025, compared to $20000.0 in Q2 2025 and $61000.0 in Q1 2025.